SGI-1776 is a novel ATP-competitive inhibitor of Pim-1, Pim-2, and Pim-3 (IC50 = 7, 363, and 69 nM, respectively). In addition to inhibiting Pim, this compound also inhibits FLT3 (IC50 = 44 nM). SGI-1776 is also cytotoxic in AML primary cells, regardless of the FLT3 mutation status, which results in Mcl-1 protein decline. SGI-1776 inhibits tumor growth for intermediate EFS T/C activity in 1 of 39 evaluable models.
Store at -20° C
~1.4 g/cm3 (Predicted)
n20D 1.61 (Predicted)
pKb: 8.93 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
CervantesCervantes-Gomez et al. (PubMed ID 26088877) found that the Pim kinase inhibitor, SGI-1776, combined with Bcl-2 antagonists in malignant chronic lymphocytic leukemia lymphocytes resulted in additive cytotoxicity. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.Hide
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.